The aim of economic evaluation is to provide information to help decision makers maximize health benefits with given resources or advise how to attain given health targets efficiently in society. However, the timing and selection of topics for HTA are challenging from the perspective of decision-making.
According to conventional Finnish practice, an HTA that includes an economic evaluation is required before a call for tenders can be given and the vaccines included in the national vaccination program. Economic evaluation can have a crucial role in this process. For instance, the inclusion of PCV was not recommended in 2002 because of insufficient cost-effectiveness, but in a second review in 2008, the recommendation was positive. As for rotavirus vaccine tenders, the predominant decision-making criterion seems to have been the cost per vaccine in spite of the cost-effectiveness analysis performed.
So far, economic evaluations have apparently been conducted using pair-wise comparisons instead of multiple comparisons, even when there have been more than two comparators (e.g. different vaccines for a certain disease are compared only to no vaccination strategy; Table 1 ). Advanced methods to synthesize evidence and to characterize uncertainty, such as mixed treatment comparisons (MTC), cost-effectiveness acceptability frontiers and value-of-information analyses, have not yet been applied. 1 These facts reduce the opportunities for using cost-effectiveness as a key decision making criterion.
THE ROLE OF ECONOMIC EVALUATION IN THE HEALTH TECHNOLOGY ASSESSMENT (HTA) OF VACCINES -LESSONS LEARNED FROM FINLAND
No specific cost-effectiveness threshold for new vaccines has been set in Finland, although international references and Finnish home dialysis and bypass surgery thresholds have been cited in economic evaluation reports. [2] [3] [4] However, setting a threshold may be impossible, because there may be variation in the willingness of decision makers to pay for the prevention of different types of diseases in different population groups. We thus present an optimal economic evaluation process that enables value-based threshold pricing for manufacturers and cost-effectiveness-based decisions that can lead to increased efficiency, even in a monopoly market (Figure 1 ).
Figure 1. An optimal economic evaluation process of vaccines in Finland
There is a discrepancy between the scientific principles and objectives of economic evaluation and real life in terms of the national economic evaluations of vaccines and calls for tender in Finland. The current practice does not necessarily lead to optimal health policy decisions that are based on cost-effectiveness and health benefit maximization. As a matter of fact, economic evaluation (cost-effectiveness) can prevent a vaccine from being included in the national vaccination program, and even after a positive HTA recommendation, the final decision may be based mostly on cost-minimization.
Discounted prices given in a tender can affect the cost-effectiveness of certain vaccines as compared to having no vaccination strategy at all or to using substitute vaccines. This should be taken into account in the economic evaluation process (Figure 1 ). In particular, transparent, fast and iterative evaluation processes that include multiple comparisons with valid prices should be encouraged.
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